Anti-CFH Monoclonal Antibody GT103

Phase 2Biologic

Anti-CFH Monoclonal Antibody GT103 is one of 43 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Advanced Lung Non-Small Cell CarcinomaRecruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Advanced Lung Non-Small Cell CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 10

Anti-CFH Monoclonal Antibody GT103

RRoswell Park Cancer Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Advanced Lung Non-Small Cell Carcinoma

NCT07017829

Clinical

Trials by Indication[1]

Advanced Lung Non-Small Cell Carcinoma1 trial

A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT07017829·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-CFH Monoclonal Antibody GT103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-CFH Monoclonal Antibody GT103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-CFH Monoclonal Antibody GT103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRoswell Park Cancer Institute

Anti-CFH Monoclonal Antibody GT103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Advanced Lung Non-Small Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News